TP Therapeutics

Cancer / Targeted Therapies


HBM contact: Dr Chandra P. Leo

Company status: private

TP Therapeutics is a clinical-stage precision oncology company, founded by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib. TP Therapeutics is developing a pipeline of novel cancer drugs designed to overcome resistance to available targeted therapies. The company's lead program is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and other advanced solid tumors. Mounting clinical data for the company’s lead program has shown ongoing antitumor activity and durable responses among treatment-naïve and pre-treated patients. With additional programs underway to address similarly intractable oncogenic drivers, TP Therapeutics is marking a turning point in the way solid-tumor cancers are treated. TP Therapeutics is located in San Diego, USA.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171